| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $376,809 | 3 | 19 |
Sells | $927,395 | 13 | 81 |
| Jain Mudit K. | director | 2 | $300,377 | 0 | $0 | $300,377 |
| Binkowski Brent | CHIEF OPERATING OFFICER | 1 | $76,432 | 1 | $3,338 | $73,094 |
| Adamson Philip B. | Chief Medical Officer | 0 | $0 | 1 | $9,973 | $-9,973 |
| VERRASTRO PAUL | CHIEF MKTG & STRAT OFFICER | 0 | $0 | 1 | $10,146 | $-10,146 |
| OASHEIM JARED | CHIEF FINANCIAL OFFICER | 0 | $0 | 1 | $13,781 | $-13,781 |
| John Robert Allen | Chief Revenue Officer | 0 | $0 | 1 | $31,326 | $-31,326 |
| Hykes Kevin | PRES & CEO | 0 | $0 | 1 | $61,349 | $-61,349 |
| JOHNSON & JOHNSON | 10 percent owner | 0 | $0 | 7 | $797,482 | $-797,482 |
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside …
Over the last 12 months, insiders at CVRx, Inc. have bought $376,809 and sold $927,395 worth of CVRx, Inc. stock.
On average, over the past 5 years, insiders at CVRx, Inc. have bought $760,593 and sold $296,229 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Jain Mudit K. (director) — $300,377. Binkowski Brent (CHIEF OPERATING OFFICER) — $76,432.
The last purchase of 26,223 shares for transaction amount of $76,432 was made by Binkowski Brent (CHIEF OPERATING OFFICER) on 2026‑08‑13.
| 2026-08-13 | Binkowski Brent | CHIEF OPERATING OFFICER | 26,223 0.098% | $2.91 | $76,432 | -8.16% | ||
| 2026-08-12 | Sale | Binkowski Brent | CHIEF OPERATING OFFICER | 1,309 0.0046% | $2.55 | $3,338 | -0.73% | |
| 2026-03-02 | Sale | Hykes Kevin | PRES & CEO | 7,763 0.0286% | $7.90 | $61,349 | -36.74% | |
| 2026-03-02 | Sale | OASHEIM JARED | CHIEF FINANCIAL OFFICER | 1,744 0.0064% | $7.90 | $13,781 | -36.74% | |
| 2026-03-02 | Sale | John Robert Allen | Chief Revenue Officer | 3,964 0.0146% | $7.90 | $31,326 | -36.74% | |
| 2026-03-02 | Sale | Adamson Philip B. | Chief Medical Officer | 1,262 0.0046% | $7.90 | $9,973 | -36.74% | |
| 2026-03-02 | Sale | VERRASTRO PAUL | CHIEF MKTG & STRAT OFFICER | 1,284 0.0047% | $7.90 | $10,146 | -36.74% | |
| 2026-02-20 | Jain Mudit K. | director | 46,800 0.1851% | $6.36 | $297,592 | -13.75% | ||
| 2026-02-18 | Jain Mudit K. | director | 600 0.0022% | $4.64 | $2,785 | +8.66% | ||
| 2025-11-26 | Sale | JOHNSON & JOHNSON | 10 percent owner | 6,337 0.0247% | $10.03 | $63,560 | -41.61% | |
| 2025-11-25 | Sale | JOHNSON & JOHNSON | 10 percent owner | 16,000 0.0622% | $10.03 | $160,480 | -42.54% | |
| 2025-11-24 | Sale | JOHNSON & JOHNSON | 10 percent owner | 2,200 0.0086% | $10.06 | $22,132 | -41.46% | |
| 2025-11-21 | Sale | JOHNSON & JOHNSON | 10 percent owner | 500 0.0019% | $10.00 | $5,000 | -41.32% | |
| 2025-11-12 | Sale | JOHNSON & JOHNSON | 10 percent owner | 1,000 0.0039% | $10.00 | $10,000 | -37.60% | |
| 2025-11-07 | Sale | JOHNSON & JOHNSON | 10 percent owner | 200 0.0008% | $10.00 | $2,000 | -38.83% | |
| 2025-11-06 | Sale | JOHNSON & JOHNSON | 10 percent owner | 52,332 0.2005% | $10.21 | $534,310 | -40.65% | |
| 2025-05-15 | Nielsen Kirk G. | director | 10,966 0.0371% | $5.45 | $59,795 | +23.42% | ||
| 2025-05-14 | Nielsen Kirk G. | director | 61,200 0.2323% | $5.23 | $320,364 | +44.42% | ||
| 2025-05-13 | Nielsen Kirk G. | director | 101,413 0.3781% | $5.29 | $536,313 | +40.44% | ||
| 2025-05-13 | Jain Mudit K. | director | 150 0.0006% | $5.26 | $789 | +40.44% |
| Jain Mudit K. | director | 980183 3.6791% | $1.35M | 10 | 0 | <0.0001% |
| Hykes Kevin | PRES & CEO | 284237 1.0669% | $392,247.06 | 2 | 1 | +33.91% |
| Binkowski Brent | CHIEF OPERATING OFFICER | 56514 0.2121% | $77,989.32 | 1 | 1 | |
| NEW ENTERPRISE ASSOCIATES 10 L P | 10 percent owner | 2026083 7.605% | $2.8M | 1 | 0 | <0.0001% |
| NEA PARTNERS 10 L P | 10 percent owner | 2026083 7.605% | $2.8M | 1 | 0 | <0.0001% |
| Nielsen Kirk G. | director | 1910134 7.1697% | $2.64M | 12 | 0 | +36.69% |
| Pardo Geoffrey B | director | 1829022 6.8653% | $2.52M | 1 | 0 | <0.0001% |
| GLAXOSMITHKLINE PLC | 10 percent owner | 1007583 3.782% | $1.39M | 1 | 0 | <0.0001% |
| SLATTERY JOSEPH P | director | 30645 0.115% | $42,290.10 | 3 | 0 | +6.29% |
| NEHRA JOHN M | director | 28266 0.1061% | $39,007.08 | 3 | 0 | <0.0001% |
| Increased Positions | 38 | +33.04% | 2M | +15.83% |
| Decreased Positions | 46 | -40% | 1M | -7.45% |
| New Positions | 9 | New | 1M | New |
| Sold Out Positions | 12 | Sold Out | 300,274 | Sold Out |
| Total Postitions | 107 | -6.96% | 15M | +8.38% |
| Johnson & Johnson | $29,134.00 | 15.78% | 4.1M | 0 | 0% | 2025-09-30 |
| Nea Management Company, Llc | $14,385.00 | 7.79% | 2.03M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $7,741.00 | 4.19% | 1.09M | +12,948 | +1.2% | 2025-09-30 |
| Blackrock, Inc. | $7,211.00 | 3.91% | 1.02M | -10,316 | -1% | 2025-09-30 |
| Balyasny Asset Management L.P. | $4,943.00 | 2.68% | 696,260 | +21,575 | +3.2% | 2025-09-30 |
| Parkman Healthcare Partners Llc | $3,489.00 | 1.89% | 491,408 | -297,691 | -37.73% | 2025-09-30 |
| Morgan Stanley | $3,064.00 | 1.66% | 431,551 | +63,300 | +17.19% | 2025-09-30 |
| Geode Capital Management, Llc | $2,875.00 | 1.56% | 404,955 | +22,518 | +5.89% | 2025-09-30 |
| Silvercrest Asset Management Group Llc | $2,552.00 | 1.38% | 359,376 | -10,455 | -2.83% | 2025-09-30 |
| State Street Corp | $2,097.00 | 1.14% | 295,391 | +655 | +0.22% | 2025-09-30 |